



# MINUTES

Utah Department of Health  
Pharmacy and Therapeutics Committee

Thursday, August 17, 2017  
7:15 a.m. to 8:45 a.m.  
Cannon Health Building  
Room 128

**Committee Members Present:**

Abril Atherton, PharmD  
Clayton Grace, RPh  
Jake Jones, MD

Susan Siegfried, MD  
Keith Tolman, MD  
Bryan Larson, PharmD

**Committee Members Excused:**

Clinton Sheffield, MD

Elizabeth Young, PharmD

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Sue Leong, RPh., Pharmacy Director  
Robyn Seely, PharmD  
Andrea Rico, CPhT

Alyssa Pitts, RN  
Heather Santacruz, RN

**University of Utah Drug Regimen Review Center Staff Presenter:**

Elena Martinez Alonso, BPharm MSc MTSI, Medical Writer

**Other Individuals Present:**

Keri Smith, Viiv Healthcare  
David Large, Supernus Pharmaceuticals  
Clayne Garrett, Boehringer  
Joanne LaFleur, U of U

Cody Ball, SelectHealth  
Brent Wright, Boehringer  
Lori Howarth, Bayer  
Charissa Anne, J&J

Meeting conducted by: Committee Chair

---

1. **Welcome & Housekeeping:** Bryan Larson opened the meeting and reminded everyone to sign the rosters.
2. **Review and Approval of June Minutes:** Bryan Larson made a motion to approve the minutes from June with the deletion of “choose a person” under staff present section. Keith Tolman seconded the motion. Unanimous approval.
3. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss Initial Prior Authorization on New NDCs and Benzodiazepines & ADD/ADHD Therapies.
4. **Long-Acting Anticholinergic, Beta-2 Agonist Combination Inhalers:** Elena Martinez Alonso presented a review of Long-Acting Anticholinergic, Beta-2 Agonist Combination Inhalers. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment

guidelines and Utah Medicaid utilization data.

5. **Public Comment:** Brent Wright presented information on Stiolto Respimat. Respimat is the only inhaler on the market that does not require inspiratory effort. Mr. Wright stated that there are no head-to-head comparisons for this class of medications.
6. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States' Medicaid programs.
7. **Committee Discussion:** Keith Tolman stated that all medications in this class are equally safe and efficacious. Keith Tolman suggested adding this class of medications to the preferred drug list. Bryan Larson stated these medications are currently on the PDL with other anti-asthmatics and suggested dividing them out. Bryan Larson motioned to separate the LABA/LAMA combinations from the anti-asthmatic combinations and motion they are equally safe and effective for inclusion on the PDL. Keith Tolman seconded. Unanimous approval.
8. **Public Meeting Adjourned:** Keith Tolman motioned to adjourn the meeting. Bryan Larson seconded the motion. Unanimous Approval.
9. **Next meeting is scheduled for** September 21, 2017 Opioid Dependence Treatments.

---

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>